Glaukos (NYSE:GKOS) Shares Climb 3.9% – Here’s What Happened

Glaukos Corporation (NYSE:GKOS) shares rose 3.9% during mid-day trading on Wednesday. The stock traded as high as $173.95 and last traded at $167.8450. Approximately 155,260 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 852,006 shares. The stock had previously closed at $161.59.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Durable Epioxa results support the corneal portfolio. Three-year Phase 3 extension data for Epioxa in keratoconus showed sustained efficacy and a favorable safety profile after a single treatment. The results strengthen the potential for a durable treatment benefit and may improve confidence in Glaukos’ corneal disease strategy. Glaukos’ Epioxa Shows Durable Three-Year Results in Keratoconus
• Positive Sentiment: Glaukos expanded its retina pipeline. The company entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, described as a first-in-class tri-specific biologic for retinal diseases. The deal broadens Glaukos’ growth opportunities beyond its existing surgical and corneal products, although the asset remains subject to development and regulatory risk. Glaukos and RevOpsis License Agreement
• Neutral Sentiment: Third-quarter results are scheduled for October 28. Investors will be watching the upcoming report for revenue growth, operating performance and updates on Epioxa and the retina pipeline. Glaukos’ most recently reported quarter showed revenue growth above 49% year over year and an adjusted loss narrower than analysts expected. Glaukos to Release Third Quarter 2026 Financial Results
• Negative Sentiment: Insider selling pressured sentiment. Reports indicated that insider transactions overshadowed the favorable Epioxa data, prompting concern among some investors about near-term valuation or management confidence. This selling-related pressure helps explain why the stock did not respond more positively to the clinical update. Glaukos Slips as Insider Selling Overshadows Positive Trial Data

Wall Street Analyst Weigh In

GKOS has been the subject of several research analyst reports. Needham & Company LLC upped their price target on shares of Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Stifel Nicolaus upped their price objective on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Citigroup boosted their target price on Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, BTIG Research raised their price target on shares of Glaukos from $193.00 to $202.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $180.54.

Glaukos Price Performance

The company has a market capitalization of $9.49 billion, a P/E ratio of -49.49 and a beta of 0.69. The company’s 50-day moving average price is $172.99 and its two-hundred day moving average price is $145.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. Glaukos’s quarterly revenue was up 49.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) EPS. As a group, sell-side analysts expect that Glaukos Corporation will post -0.32 EPS for the current year.

Insider Transactions at Glaukos

In related news, Director Leana Wen sold 525 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director directly owned 21,092 shares in the company, valued at $3,535,651.96. The trade was a 2.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Alex Thurman sold 20,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 93,025 shares of company stock valued at $16,550,006. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Wealth Alliance LLC boosted its holdings in shares of Glaukos by 4.5% during the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 98 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Glaukos by 25.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 138 shares in the last quarter. Allworth Financial LP bought a new position in Glaukos in the second quarter valued at about $28,000. CoreCap Advisors LLC bought a new position in Glaukos in the third quarter valued at about $33,000. Finally, Parallel Advisors LLC boosted its stake in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products intended to preserve and restore vision. The company’s primary business is minimally invasive glaucoma surgery (MIGS), which is designed to reduce intraocular pressure and potentially lessen patients’ dependence on glaucoma medications.

Glaukos’ glaucoma portfolio includes the iStent, iStent inject and iStent infinite systems, which are used in procedures to improve the eye’s natural fluid outflow.